Alvotech and Teva Progress on AVT05 Biosimilar Development
Alvotech (NASDAQ: ALVO), a leading biotech company dedicated to creating biosimilar medicines, has joined forces with Teva Pharmaceuticals to advance the U.S. Biologics License Applications (BLA) for AVT05. This proposed biosimilar targets Simponi® and Simponi Aria® (golimumab), widely utilized for treating various inflammatory conditions.
FDA Review and Expectations
The U.S. Food and Drug Administration (FDA) recently accepted these applications for review, marking a historic milestone as they represent the inaugural BLA filings for a biosimilar candidate to golimumab in the U.S. The review process is expected to conclude during the latter part of 2025, which brings hope for increased patient access to alternative treatments once approved.
Significance of AVT05
Joseph McClellan, Chief Scientific Officer of Alvotech, emphasized the importance of this development, stating, "This is a significant step towards being able to offer U.S. patients access to biosimilar golimumab." The company believes that its advanced manufacturing capabilities, including matching the cell line and processes of the reference biologic, provide a competitive advantage in the biosimilar space.
Collaborative Efforts with Teva
Teva’s Senior Vice President for U.S. Biosimilars, Thomas Rainey, further highlighted the partnership, indicating that biosimilars are transforming the treatment landscape and are becoming essential for patient care. He shared that this alliance underscores Teva's commitment to delivering cost-effective options that improve patient outcomes for those suffering from inflammatory diseases.
Recent Clinical Study Results
In April 2024, Alvotech announced positive findings from a clinical study that explored the efficacy, safety, and immunogenicity of AVT05 compared to Simponi® for patients battling moderate to severe rheumatoid arthritis. Earlier, in November 2023, another study assessed the pharmacokinetics and tolerability of AVT05 in healthy adults, which also yielded promising results.
Expanding Commercialization Partnerships
Since the formation of their strategic partnership in August 2020, Alvotech and Teva have seen remarkable progress. This alliance initially focused on five biosimilar product candidates, and has since expanded to cover nine. Alvotech oversees development and manufacturing, utilizing its innovative technology, while Teva manages the commercialization with its vast infrastructure.
Achievements in the Biosimilar Market
The partnership has seen notable successes, with two biosimilars receiving FDA approval since its inception. In February 2024, SIMLANDI® (adalimumab-ryvk) became the first high-concentration, citrate-free interchangeable biosimilar to Humira® (adalimumab), officially available in the U.S. in May 2024. Additionally, SELARSDI™ (ustekinumab-aekn) gained approval as a biosimilar to Stelara® (ustekinumab) in April 2024, set to enter the U.S. market by February 2025.
Understanding AVT05 and Its Potential
AVT05 is being developed as a biosimilar candidate for Simponi® and Simponi Aria®. Golimumab, the target of AVT05, is a monoclonal antibody effective in inhibiting tumor necrosis factor alpha (TNF alpha), a critical factor implicated in numerous chronic inflammatory diseases like rheumatoid arthritis and psoriatic arthritis. As an investigational product, AVT05 has not yet received regulatory approval, and its biosimilarity is still under evaluation.
About Alvotech and Teva
Alvotech, established by Robert Wessman, specializes in producing biosimilar medicines with the goal of becoming a global leader in this sector. The company prides itself on high-quality, cost-effective therapies driven by a strong development pipeline. Teva Pharmaceutical Industries Ltd. has an extensive history of advancing pharmaceutical innovation and has played a pivotal role in the growth of both generic and biosimilar markets.
Future Outlook
The journey toward the approval and commercialization of AVT05 signifies a broader commitment from both companies to enhance patient access to essential treatments. The partnership reflects a proactive approach to meet the healthcare demands of patients globally.
Frequently Asked Questions
What is AVT05?
AVT05 is a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), targeting inflammatory conditions and currently under FDA review.
What role do Alvotech and Teva play in AVT05?
Alvotech is responsible for developing AVT05, while Teva manages its commercialization in the U.S., combining their strengths to enhance patient access to biosimilars.
What successes have Alvotech and Teva achieved in their partnership?
Since their partnership began, two biosimilars have received FDA approval, enhancing their portfolio and contributing to improved patient treatment options.
When is the FDA expected to complete its review of AVT05?
The FDA review process for AVT05 is anticipated to conclude by the fourth quarter of 2025.
How do biosimilars affect treatment options?
Biosimilars increase competition in the market, typically leading to lower prices and expanded access to vital medications for patients with chronic conditions.
